AM201

Bispecific antibody treatment for autoimmune diseases (rheumatoid arthritis)

AM201 is a bispecific antibody capable of simultaneously targeting TNF-α and IL6 to treat autoimmune diseases

Since AM201 targets both TNF-α and IL6 disease proteins, it is expected to have
excellent therapeutic effects against autoimmune diseases. Its bispecific nature also
means that a smaller dose would need to be administered than a cocktail combination of
TNF-α and IL6 inhibitors. AM201’s scope of treatments will be expanded to various
other diseases such as cytokine release syndrome.

Excellent effects when benchmarked against Humira in SAA
(inflammatory protein) animal model

In efficacy tests involving inflammatory protein (SAA) animal models, treatment efficacy
of AM201 was undiminished despite being administered at a lower dosage compared to Humira.

Designed by CHAIRONE

AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
T. +82-2109-1294
F. +82-2109-1296
E. abclon@abclon.com

AM201

Bispecific antibody treatment for autoimmune diseases (rheumatoid arthritis)

Excellent effects when benchmarked against Humira in SAA (inflammatory protein) animal model

Excellent effects when benchmarked against Humira in SAA
(inflammatory protein) animal model